{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T08:21:11Z","timestamp":1649060471344},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Intercept Pharmaceuticals"},{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.cld.2018.03.004","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T23:04:00Z","timestamp":1526598240000},"page":"501-515","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Work in Progress"],"prefix":"10.1016","volume":"22","author":[{"given":"Gwilym J.","family":"Webb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2018.03.004_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pathol-020712-164014","article-title":"The immunobiology and pathophysiology of primary biliary cirrhosis","volume":"8","author":"Hirschfield","year":"2013","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.cld.2018.03.004_bib2","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2018.03.004_bib3","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis","volume":"39","author":"Poupon","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib5","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.4065\/72.12.1137","article-title":"Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis","volume":"72","author":"Lindor","year":"1997","journal-title":"Mayo Clinic Proc"},{"issue":"2","key":"10.1016\/j.cld.2018.03.004_bib6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.cgh.2017.09.062","article-title":"Twenty-year comparative analysis of patients with autoimmune liver diseases on transplant waitlists","volume":"16","author":"Webb","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2018.03.004_bib8","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2018.03.004_bib9","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2018.03.004_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000551.pub2","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","author":"Gong","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.cld.2018.03.004_bib11","article-title":"Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis","author":"Saffioti","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.cld.2018.03.004_bib12","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cld.2018.03.004_bib13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Hirschfield","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2018.03.004_bib16","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2010.05.026","article-title":"The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: results of a 9 year follow-up","volume":"53","author":"Jones","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/liv.12560","article-title":"Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis","volume":"35","author":"Quarneti","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.cld.2018.03.004_bib18","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2018.03.004_bib19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2018.03.004_bib20","article-title":"A\u00a0randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","author":"Kowdley","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib21","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.cld.2018.03.004_bib22","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/hep.29511","article-title":"Chronic elevation of plasma FGF19 in long-term FXR agonist therapy, a happy marriage or cause for oncologic concern?","volume":"67","author":"Schaap","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib23","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","article-title":"Identification of a nuclear receptor for bile acids","volume":"284","author":"Makishima","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.cld.2018.03.004_bib24","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","article-title":"Bile acids: natural ligands for an orphan nuclear receptor","volume":"284","author":"Parks","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.cld.2018.03.004_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrgastro.2013.151","article-title":"Bile acid receptors as targets for drug development","volume":"11","author":"Schaap","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","article-title":"Bile acid transporters and regulatory nuclear receptors in the liver and beyond","volume":"58","author":"Halilbasic","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib27","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"issue":"24","key":"10.1016\/j.cld.2018.03.004_bib28","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and Nonalcoholic Steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cld.2018.03.004_bib29","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1172\/JCI18945","article-title":"Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis","volume":"112","author":"Liu","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cld.2018.03.004_bib30","doi-asserted-by":"crossref","first-page":"G940","DOI":"10.1152\/ajpgi.00398.2012","article-title":"Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids","volume":"304","author":"Zhang","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.cld.2018.03.004_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1507\/endocrj.KR07E-002","article-title":"Actions and mode of actions of FGF19 subfamily members","volume":"55","author":"Fukumoto","year":"2008","journal-title":"Endocr J"},{"key":"10.1016\/j.cld.2018.03.004_bib32","first-page":"216A","article-title":"NGM282, a Potent Inhibitor of CYP7A1, Prevents FGF19-Mediated HCC Tumor Development in db\/db and rasH2 Mice","volume":"60","author":"Ling","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib33","first-page":"520A","article-title":"Impact of NGM282 on the incidence and severity of pruritus in primary biliary cirrhosis patients and correlations with liver chemistries and serum bile acids","volume":"62","author":"Mayo","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib34","doi-asserted-by":"crossref","first-page":"S1315","DOI":"10.1016\/S0016-5085(17)34375-5","article-title":"NGM282, variant of FGF19, is a gastric and colonic prokinetic and stimulates bowel function in patients with functional constipation: phase 1B, two-dose, placebo controlled study","volume":"152","author":"Oduyebo","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2018.03.004_bib35","doi-asserted-by":"crossref","first-page":"S531","DOI":"10.1016\/S0168-8278(14)61475-6","article-title":"Hepatoprotective effects of NGM282 compared to obeticholic acid and bezafibrate in mouse models of cholestasis","volume":"60","author":"Luo","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib36","first-page":"263A","article-title":"NGM282, a novel variant of FGF-19, demonstrates biologic activity in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid: results of a phase 2 multicenter, randomized, double blinded, placebo controlled trial","volume":"62","author":"Mayo","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S2213-8587(16)30155-3","article-title":"Clinical relevance of the bile acid receptor TGR5 in metabolism","volume":"5","author":"van Nierop","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cld.2018.03.004_bib38","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jhep.2010.12.004","article-title":"The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation","volume":"54","author":"Pols","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1515\/bc.2010.077","article-title":"The membrane-bound bile acid receptor TGR5 (Gpbar-1) is localized in the primary cilium of cholangiocytes","volume":"391","author":"Keitel","year":"2010","journal-title":"Biol Chem"},{"key":"10.1016\/j.cld.2018.03.004_bib40","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI64551","article-title":"The TGR5 receptor mediates bile acid-induced itch and analgesia","volume":"123","author":"Alemi","year":"2013","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.cld.2018.03.004_bib41","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1053\/j.gastro.2014.08.042","article-title":"The bile acid receptor TGR5 activates the TRPA1 channel to induce itch in mice","volume":"147","author":"Lieu","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2018.03.004_bib42","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/hep.24525","article-title":"The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice","volume":"54","author":"Wang","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib43","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2-\/- (Abcb4-\/-) mouse cholangiopathy model by promoting biliary HCO(-)(3) output","volume":"54","author":"Baghdasaryan","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.cld.2018.03.004_bib45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.cld.2018.03.004_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.cld.2018.03.004_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cld.2018.03.004_bib48","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0168-8278(17)30442-7","article-title":"2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)","volume":"66","author":"Corpechot","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib49","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib50","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib51","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-alpha and -delta, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2018.03.004_bib52","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaut.2015.07.004","article-title":"The immunogenetics of primary biliary cirrhosis: a comprehensive review","volume":"64","author":"Webb","year":"2015","journal-title":"J\u00a0Autoimmun"},{"issue":"5","key":"10.1016\/j.cld.2018.03.004_bib53","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/hep.26979","article-title":"IL-12\/Th1 and IL-23\/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib54","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1023\/A:1020511002025","article-title":"Cytokine profile in the liver of primary biliary cirrhosis","volume":"19","author":"Nagano","year":"1999","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.cld.2018.03.004_bib55","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/hep.23132","article-title":"Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor \u03b2 receptor type II mice","volume":"50","author":"Yoshida","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib57","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0168-8278(02)00065-X","article-title":"Up-regulated expression of fractalkine and its receptor CX3CR1 during liver injury in humans","volume":"37","author":"Efsen","year":"2002","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib58","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/hep.23318","article-title":"CX3CL1 (fractalkine): a signpost for biliary inflammation in primary biliary cirrhosis","volume":"51","author":"Shimoda","year":"2010","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2018.03.004_bib59","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/14397595.2017.1337056","article-title":"Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1\/2 study on rheumatoid arthritis","volume":"28","author":"Tanaka","year":"2018","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.cld.2018.03.004_bib60","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13148-015-0098-9","article-title":"DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis","volume":"7","author":"Lleo","year":"2015","journal-title":"Clin Epigenetics"},{"issue":"3","key":"10.1016\/j.cld.2018.03.004_bib61","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/cei.12193","article-title":"Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis","volume":"174","author":"Tanaka","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cld.2018.03.004_bib62","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.cld.2018.03.004_bib63","doi-asserted-by":"crossref","first-page":"14828","DOI":"10.1038\/ncomms14828","article-title":"A\u00a0genome-wide association study identifies six novel risk loci for primary biliary cholangitis","volume":"8","author":"Qiu","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.cld.2018.03.004_bib64","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/hep.26067","article-title":"Therapeutic effect of cytotoxic T lymphocyte antigen 4\/immunoglobulin on a murine model of primary biliary cirrhosis","volume":"57","author":"Dhirapong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib65","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bbalip.2012.07.002","article-title":"Targeting the sphingosine kinase\/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors","volume":"1831","author":"Orr Gandy","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cld.2018.03.004_bib66","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A\u00a0placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2018.03.004_bib67","unstructured":"Peyrin-Biroulet L, Christopher R, Trokan L, et\u00a0al. Safety, pharmacokinetics and pharmacodynamics of etrasimod (APD334), an oral, selective S1P receptor modulator, after single dose escalation in healthy volunteers. 2016. Available at: https:\/\/www.ecco-ibd.eu\/publications\/congress-abstract-s\/abstracts-2017\/item\/p369-safety-and-lymphocyte-lowering-properties-of-etrasimod-apd334-an-oral-potent-next-generation-selective-s1p-receptor-modulator-after-dose-escalation-in-healthy-volunteers-2.html. Accessed April 18, 2018."},{"key":"10.1016\/j.cld.2018.03.004_bib68","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","volume":"36","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.cld.2018.03.004_bib69","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2018.03.004_bib70","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2018.03.004_bib71","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.cld.2018.03.004_bib72","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000440829","article-title":"Pathogenesis and management of pruritus in PBC and PSC","volume":"33","author":"Kremer","year":"2015","journal-title":"Dig Dis"},{"key":"10.1016\/j.cld.2018.03.004_bib73","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.25748","article-title":"Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions","volume":"56","author":"Kremer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib74","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0140-6736(17)30319-7","article-title":"Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study","volume":"389","author":"Hegade","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2018.03.004_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mrrev.2004.08.001","article-title":"Bile acids as carcinogens in human gastrointestinal cancers","volume":"589","author":"Bernstein","year":"2005","journal-title":"Mutat Res"},{"key":"10.1016\/j.cld.2018.03.004_bib76","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s005350170111","article-title":"The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples","volume":"36","author":"Kisand","year":"2001","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.cld.2018.03.004_bib77","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hep.28859","article-title":"Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis","volume":"65","author":"Dahlqvist","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2018.03.004_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198201073060101","article-title":"Recurrence of primary biliary cirrhosis after liver transplantation","volume":"306","author":"Neuberger","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cld.2018.03.004_bib79","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jhep.2015.07.038","article-title":"Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence","volume":"63","author":"Bosch","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib80","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/lt.21124","article-title":"Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation","volume":"13","author":"Charatcharoenwitthaya","year":"2007","journal-title":"Liver Transplant"},{"key":"10.1016\/j.cld.2018.03.004_bib81","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1111\/ajt.12132","article-title":"Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation","volume":"13","author":"Carbone","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cld.2018.03.004_bib82","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MJT.0000000000000387","article-title":"A\u00a0randomized, placebo-controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis","volume":"24","author":"Silveira","year":"2017","journal-title":"Am J Ther"},{"key":"10.1016\/j.cld.2018.03.004_bib83","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/S0168-8278(17)30451-8","article-title":"LBP-506-B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cholangitis: a randomised controlled trial (RITPBC)","volume":"66","author":"Jopson","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2018.03.004_bib84","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nature16962","article-title":"Expanding antigen-specific regulatory networks to treat autoimmunity","volume":"530","author":"Clemente-Casares","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.cld.2018.03.004_bib85","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T\u00a0cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cld.2018.03.004_bib86","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1038\/ncomms3384","article-title":"Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity","volume":"4","author":"Li","year":"2013","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.cld.2018.03.004_bib87","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1136\/gutjnl-2016-313332","article-title":"Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy","volume":"67","author":"Tang","year":"2018","journal-title":"Gut"},{"issue":"6371","key":"10.1016\/j.cld.2018.03.004_bib88","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.cld.2018.03.004_bib89","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.1001529107","article-title":"Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation","volume":"107","author":"Albers","year":"2010","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326118300291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326118300291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T16:41:55Z","timestamp":1534869715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326118300291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S1089326118300291"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2018.03.004","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Work in Progress","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2018.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}